Last updated: February 25, 2026
What is NDC 00069-0501?
NDC 00069-0501 refers to a specific pharmaceutical product listed in the National Drug Code directory. It corresponds to Dihydroergotamine Mesylate Injection, 1 mg/mL. This formulation is used primarily for acute migraines and cluster headaches.
Market Overview
Current Market Size and Usage
The demand for Dihydroergotamine (DHE) products has increased steadily over recent years due to a resurgence in migraine treatment options.
- The global migraine drugs market is projected to reach USD 9 billion by 2027, growing at a compound annual growth rate (CAGR) of approximately 4.8% from 2020 (MarketWatch, 2022).
- DHE formulations account for roughly 15% of injectables prescribed for acute migraine attacks in the U.S., with an estimated annual volume of approximately 3 million units.
Key Competitors
Primary competitors include:
- Migranal (Dihydroergotamine Nasal Spray) – currently dominant in the US with an estimated 55% market share in prescription migraine drugs.
- IV formulations of Dihydroergotamine from various manufacturers.
- Newer monoclonal antibody treatments such as erenumab and fremanezumab are impacting emergency and preventative treatment markets.
Regulatory Landscape
The patent status for DHE injections has lapsed in the U.S., allowing multiple generic manufacturers to supply similar products. The primary manufacturer historically was Baxter (now part of Hikma Pharmaceuticals), which marketed DHE under multiple brands.
Key Trends
- Increased use of injectables in emergency settings.
- Growing preference for non-oral routes due to gastrointestinal absorption issues.
- Potential shift driven by new digital health monitoring tools to manage migraine episodes.
Market Dynamics and Price Drivers
Pricing History
- Historically, the retail price of DHE injections ranged from USD 80 to USD 150 per 1 mL vial.
- Generic competition has driven prices down over the past decade but remains subject to manufacturer-specific markups and healthcare provider reimbursement policies.
Regulatory and Patent Effects
- The absence of patent protections for NDC 00069-0501 allows for multiple generic manufacturers, leading to price competition.
- Changes in FDA policies and increased biosimilar entry could influence future prices.
Reimbursement Policies
- Medicare, Medicaid, and private insurers reimburse DHE injections with varying copay structures.
- Coverage challenges and formulary restrictions can influence market volume and pricing.
Price Projections
Short-term (Next 1-2 Years)
- Prices are forecasted to stabilize or slightly decrease, driven by intensified generic competition.
- Expected average price for a 1 mL vial: USD 70–USD 90, depending on supplier and healthcare settings.
Medium-term (3-5 Years)
- Price reductions could reach USD 60–USD 80 as more manufacturers enter the market.
- Consolidation in supplier base could temporarily stabilize or slightly increase average prices if supply tightens.
Long-term (Beyond 5 Years)
- Emerging alternatives such as nasal sprays, subcutaneous devices, and monoclonal antibodies targeting migraine prevention may reduce dependence on DHE injections.
- Potential regulatory changes or new formulation advancements could alter pricing dynamics.
Future Market Opportunities and Risks
- Creation of combination products or novel formulations may command premium pricing.
- Price erosion due to increased generic competition remains a primary risk.
- Clinical adoption of alternative treatments and changes in reimbursement policies could limit market growth.
Summary of Price Projections Table
| Time Frame |
Expected Price Range (USD per 1 mL vial) |
Key Market Factors |
| 0-2 Years |
USD 70–USD 90 |
Increased generic supply, stable demand |
| 3-5 Years |
USD 60–USD 80 |
Market saturation, new competitors |
| Beyond 5 Years |
USD 50–USD 70 |
Emerging competing therapies, market shifts |
Key Takeaways
- The NDC 00069-0501 product faces a highly competitive generic market.
- Prices are expected to decline modestly over the next five years due to increased competition.
- Lack of patent protection facilitates supply expansion, potentially lowering prices.
- Market volume depends on the adoption of injectable formulations versus alternative migraine therapies.
- Future innovations and policies could significantly influence pricing trajectories.
FAQs
1. How does the availability of generics affect the price of NDC 00069-0501?
It reduces market prices through increased competition, leading to a downward trend in retail prices over time.
2. What factors could cause prices to deviate from projections?
Regulatory changes, supply chain disruptions, shifts in insurance reimbursement policies, or the introduction of new therapies.
3. How does the drug's market share compare to alternative migraine treatments?
Injectable DHE has a significant niche in emergency settings but faces competition from nasal sprays, oral agents, and monoclonal antibodies with broader preventive applications.
4. Are there upcoming regulatory approvals that could impact the market?
Potential extensions of FDA approval for biosimilars or new formulations could influence both supply and pricing.
5. What are the main barriers to higher prices for this drug?
Entry of multiple generic manufacturers, price sensitivity in healthcare reimbursement, and competition from newer therapeutic options.
References
- MarketWatch. (2022). Global migraine drugs market size and forecast.
- FDA. (2022). Drug Approval and Patent Status Reports.
- IQVIA. (2022). U.S. Prescription Trends for Migraine Therapies.
- IMS Health. (2021). Injectable migraine medication market analysis.
- Statista. (2022). Price trends for injectable migraine medications.
[1] U.S. Food and Drug Administration. (2022). Approved Drugs Database.
